Recombinant Human Protein Wnt-10B (WNT10B) Protein (His&Myc)

Beta LifeScience SKU/CAT #: BLC-06544P
Greater than 85% as determined by SDS-PAGE.
Greater than 85% as determined by SDS-PAGE.

Recombinant Human Protein Wnt-10B (WNT10B) Protein (His&Myc)

Beta LifeScience SKU/CAT #: BLC-06544P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Protein Wnt-10B (WNT10B) Protein (His&Myc) is produced by our E.coli expression system. This is a full length protein.
Purity Greater than 85% as determined by SDS-PAGE.
Uniprotkb O00744
Target Symbol WNT10B
Species Homo sapiens (Human)
Expression System E.coli
Tag N-10His&C-Myc
Target Protein Sequence NEILGLKLPGEPPLTANTVCLTLSGLSKRQLGLCLRNPDVTASALQGLHIAVHECQHQLRDQRWNCSALEGGGRLPHHSAILKRGFRESAFSFSMLAAGVMHAVATACSLGKLVSCGCGWKGSGEQDRLRAKLLQLQALSRGKSFPHSLPSPGPGSSPSPGPQDTWEWGGCNHDMDFGEKFSRDFLDSREAPRDIQARMRIHNNRVGRQVVTENLKRKCKCHGTSGSCQFKTCWRAAPEFRAVGAALRERLGRAIFIDTHNRNSGAFQPRLRPRRLSGELVYFEKSPDFCERDPTMGSPGTRGRACNKTSRLLDGCGSLCCGRGHNVLRQTRVERCHCRFHWCCYVLCDECKVTEWVNVCK
Expression Range 29-389aa
Protein Length Full Length of Mature Protein
Mol. Weight 47.5 kDa
Research Area Others
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Member of the Wnt ligand gene family that encodes for secreted proteins, which activate the Wnt signaling cascade. Specifically activates canonical Wnt/beta-catenin signaling and thus triggers beta-catenin/LEF/TCF-mediated transcriptional programs. Involved in signaling networks controlling stemness, pluripotency and cell fate decisions. Acts in the immune system, mammary gland, adipose tissue, bone and skin.
Subcellular Location Secreted, extracellular space, extracellular matrix. Secreted.
Protein Families Wnt family
Database References

HGNC: 12775

OMIM: 225300

KEGG: hsa:7480

STRING: 9606.ENSP00000301061

UniGene: PMID: 30149605

  • We report an Indian girl with split-hand/foot malformation (SHFM), sparse hair, and interrupted eyebrows, who carries a novel homozygous deletion c.695_697delACA in WNT10B. The variant is deduced to cause an in-frame deletion of Asn residue 232 (p.Asn232del). PMID: 29427788
  • Wnt10b is involved in forskolin/hCG-mediated BeWo cell fusion via beta-catenin/GCMa/syncytin pathway, which may also involve activation of PKA PMID: 28370659
  • These results present the first evidence for a recurrent rearrangement promoted by a mobile ht-WNT10B oncogene, as a relevant mechanism for Wnt involvement in human cancer. PMID: 27853307
  • High expression of WNT10B is associated with epithelial-mesenchymal transition and invasion of pancreatic cancer. PMID: 28586066
  • this study provides novel insight into the mechanism of action of parathyroid hormone on human periodontal ligament cells and establish their interplay with T cells via the Wnt10b pathway as a modulating factor for the anabolic properties of the hormone in periodontal regeneration PMID: 28071181
  • findings provide the identification of autosomal-dominant WNT10B mutations in individuals with oligodontia, which increases the spectrum of congenital tooth agenesis and suggests attenuated Wnt signaling in endothelial differentiation of dental pulp stem cells. PMID: 27321946
  • these findings clearly demonstrate that Wnt10b promotes epidermal keratinocyte transformation through induced Egf pathway PMID: 25995040
  • Data show that Wnt protein Wnt10b is expressed in cardiomyocytes and localized in the intercalated discs of mouse and human hearts. PMID: 26338900
  • WNT10B enhances proliferation through beta-catenin and RAC1 GTPase in human corneal endothelial cells. PMID: 26370090
  • Sequence analysis of WNT10B gene revealed a novel 4-bp deletion mutation. PMID: 24211389
  • No association between WNT10B polymorphisms and adiposity parameters was found. However, a role for WNT10B variants in determining human bone mineral density was found. PMID: 23325361
  • Variations in WNT10B do not contribute to human monogenic obesity in our population. PMID: 23104151
  • Hypoxia-inducible factor-2alpha-dependent hypoxic induction of Wnt10b expression in adipogenic cells. PMID: 23900840
  • we identified WNT10B as a direct target of miR-148a in cancer-associated fibroblasts from endometrial cancers PMID: 22890324
  • WNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic breast cancer tumours devoid of ERalpha, PR and HER2 expression. PMID: 23307470
  • Results suggest that Wnt10b likely plays an important role in the development of endometrial cancer (EC). The results also identify a role for Wnt10b in EC cells through promoting proliferation and inhibiting apoptosis. PMID: 23135473
  • A novel sequence variant (c.986C>G, p.Thr329Arg) of WNT10B has been identified in familial split-hand/foot malformations in a large consanguineous Pakistani family. PMID: 21554266
  • common variation in WNT10B was shown to be associated with BMI and weight in a case-control population of Belgian males. PMID: 22189080
  • Wnt10b, but not Wnt3a, stimulates the NFkappaB and Notch pathways in U2OS osteosarcoma cells. PMID: 21321991
  • This study is the first report of the association of common genetic polymorphism of WNT10B with human fat accumulation. PMID: 20579865
  • Homozygous nonsense mutation in WNT10B is associated with sporadic split-hand/foot malformation with autosomal recessive inheritance. PMID: 20635353
  • pyrethroid insecticides and estrogen can enhance the expression of the WNT10B proto-oncogene PMID: 12437293
  • mutations represent the first naturally occurring missense variants of WNT10B PMID: 16477437
  • suggest that fibroblast growth factor switches WNT10B from a negative to a positive cell growth regulator PMID: 17761539
  • Metastatic osteosarcoma cell lines showed better chemotaxis response to Wnt10B than the non-metastatic osteosarcoma cell lines PMID: 18465804
  • By homozygosity mapping a novel Split-Hand/Foot Malformation locus at 12q13.11-q13 with a maximum multipoint lod score of 5.47; by subsequent candidate gene approach a homozygous missense WNT10b mutation was identified. PMID: 18515319
  • This analysis implicates the WNT10B locus as a genetic element in the regulation of bone mass and structural geometry. PMID: 19016593
  • In Wnt10b-expressing mammary tumors, levels of p27(KIP1) were extremely low; conversely, Wnt10b-null mammary cells expressed high levels of this protein, suggesting Wnt-dependent regulation of p27(KIP1). PMID: 19056892
  • S1P induces osteoblast precursor recruitment and promotes mature cell survival. Wnt10b and BMP6 also were significantly increased in mature osteoclasts, whereas sclerostin levels decreased during differentiation. PMID: 19075223
  • We have not found evidence for a robust association of common WNT10B gene allelic variants with either BMD or fractures in postmenopausal women. PMID: 19458884
  • FAQs

    Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

    Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

    Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

    Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

    Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

    Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

    To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

    Recently viewed